FRENCH pharmaceutical giant Sanofi today forecast slower earnings growth for 2023 after profits jumped last year on the back of popular eczema and asthma drug Dupixent.

The company’s net profit rose by 8% to €6.7 billion (RM31.15 billion) last year.

Its earnings per share, or profits divided by outstanding shares, rose by 17.1% to €8.26, but Sanofi forecast “low single-digit” growth this year.

Sanofi shares fell following the announcement.

The company’s Dupixent treatment has been a huge success for Sanofi, raking in €8.3 billion in sales last year. 

“Dupixent and Vaccines continue to be our leading growth drivers,” Sanofi chief executive Paul Hudson said in a statement.

Sanofi is aiming for €10 billion in sales of Dupixent this year. – AFP, February 3, 2023.